Telmisartan use in rats with preexisting osteoporotics bone disorders increases bone microarchitecture alterations via PPAR gamma

Imagem de Miniatura
Arquivos
art_BIROCALE_Telmisartan_use_in_rats_with_preexisting_osteoporotics_bone_2019.PDF.pdf (2.25 MB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
BIROCALE, Antonio Marcos
MELO JR., Antonio Ferreira de
PEIXOTO, Pollyana
OLIVEIRA, Phablo Wendell Costalonga
RUFFONI, Leandro Dias Goncalves
NOGUEIRA, Breno Valentim
NONAKA, Keico Okino
OLIVEIRA JR., Jose Martins de
Citação
LIFE SCIENCES, v.237, article ID 116890, 7p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims: Telmisartan (TEL), an angiotensin II type I receptor blocker and PPAR gamma partial agonist, has been used for to treat hypertension. It is known that PPAR gamma activation induces bone loss. Therefore, we evaluate the effects of telmisartan on PPAR gamma protein expression, biomechanics, density and bone microarchitecture of femurs and lumbar vertebrae in SHR ovariectomized animals, a model of hypertension in which preexisting bone impairment has been demonstrated. Main methods: SHR females (3 months old) were distributed into four groups: sham (S), sham + TEL (ST), OVX (C) and OVX + TEL (CT). TEL (5 mg/kg/day) or vehicle were administered according to the groups. After the protocol, blood pressure was measured and density, microarchitecture and biomechanics of bone were analyzed. Western blotting analysis was performed to evaluate PPAR gamma protein expression in the bones. Key findings: Castration induced a deleterious effect on mineral density and trabecular parameters, with telmisartan enhancing such effects. Telmisartan increased PPAR gamma levels, which were at their highest when the treatment was combined with castration. As to biomechanical properties, telmisartan reduced the stiffness in the castration group (CT vs. S or C group), as well as resilience and failure load in ST group (vs. all others groups). Significance: These results demonstrated that telmisartan compromised bone density and microarchitecture in animals that shows preexisting osteoporotic bone disorders, probably via mechanisms associated with increased PPAR gamma. If this translates to humans, a need for greater caution in the use of telmisartan by patients that have preexisting bone problems, as in the postmenopausal period, may be in order.
Palavras-chave
Telmisartan, PPAR gamma, Hypertension, Ovariectomy, Bone
URI
https://observatorio.fm.usp.br/handle/OPI/35385
Referências
  1. Aydogan BI, 2019, J RENIN-ANGIO-ALDO S, V20, DOI 10.1177/1470320319862741
  2. Billington EO, 2015, DIABETOLOGIA, V58, P2238, DOI 10.1007/s00125-015-3660-2
  3. Birocale AM, 2016, PHARMACOL REP, V68, P1149, DOI 10.1016/j.pharep.2016.06.014
  4. Bragdon B, 2015, J CELL PHYSIOL, V230, P296, DOI 10.1002/jcp.24705
  5. Brandi ML, 2009, RHEUMATOLOGY, V48, pIV3, DOI 10.1093/rheumatology/kep273
  6. Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140-6736(99)01437-3
  7. Chappard D., 2008, Morphologie, V92, P162, DOI 10.1016/j.morpho.2008.10.003
  8. Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9
  9. Endlich PW, 2017, PEPTIDES, V87, P41, DOI 10.1016/j.peptides.2016.11.010
  10. FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612
  11. Fortepiani LA, 2003, HYPERTENSION, V41, P640, DOI 10.1161/01.HYP.0000046924.94886.EF
  12. Gierach GL, 2006, J AM COLL CARDIOL, V47, p50S, DOI 10.1016/j.jacc.2005.02.099
  13. Ilic K, 2013, CALCIFIED TISSUE INT, V92, P217, DOI 10.1007/s00223-012-9671-9
  14. IZAWA Y, 1985, CALCIFIED TISSUE INT, V37, P605, DOI 10.1007/BF02554916
  15. Kalpakcioglu BB, 2008, J BONE JOINT SURG AM, V90A, P68, DOI 10.2106/JBJS.G.01506
  16. Kang KY, 2013, J KOREAN MED SCI, V28, P1139, DOI 10.3346/jkms.2013.28.8.1139
  17. Kishi T, 2014, AM J HYPERTENS, V27, P260, DOI 10.1093/ajh/hpt188
  18. Lim LS, 2009, J AM GERIATR SOC, V57, P855, DOI 10.1111/j.1532-5415.2009.02195.x
  19. Ma L, 2010, BONE, V47, P5, DOI 10.1016/j.bone.2010.03.016
  20. Masi L, 2008, CLIN CASES MINER BON, V5, P11
  21. Mosti MP, 2014, ENDOCRINOLOGY, V155, P2178, DOI 10.1210/en.2013-1166
  22. Ninios I, 2008, CLIN EXP HYPERTENS, V30, P327, DOI 10.1080/10641960802269943
  23. Ott SM, 2008, OSTEOPOROSIS INT, V19, P1315, DOI 10.1007/s00198-008-0612-4
  24. Pang J, 2015, REJUV RES, V18, P356, DOI 10.1089/rej.2015.1682
  25. Paniagua JG, 1998, BRIT J RADIOL, V71, P754, DOI 10.1259/bjr.71.847.9771386
  26. Patullo IMF, 2009, ORAL DIS, V15, P580, DOI 10.1111/j.1601-0825.2009.01599.x
  27. Perez-Castrillon JL, 2005, CURR HYPERTENS REV, V1, P61, DOI 10.2174/1573402052952843
  28. Pietschmann Peter, 2004, Wien Med Wochenschr, V154, P411, DOI 10.1007/s10354-004-0100-1
  29. Rajkumar C, 1997, J AM COLL CARDIOL, V30, P350, DOI 10.1016/S0735-1097(97)00191-5
  30. Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140-6736(06)68891-0
  31. Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07-098954
  32. Solomon DH, 2011, J BONE MINER RES, V26, P1561, DOI 10.1002/jbmr.356
  33. Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223-004-0224-8
  34. Staessen JA, 1997, J HUM HYPERTENS, V11, P507, DOI 10.1038/sj.jhh.1000476
  35. Stunes AK, 2011, BMC ENDOCR DISORD, V11, DOI 10.1186/1472-6823-11-11
  36. Susic D, 2014, J AM SOC HYPERTENS, V8, P297, DOI 10.1016/j.jash.2014.02.009
  37. THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756-3282(95)00285-L
  38. Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
  39. Trebacz H, 2006, J BIOMECH, V39, P237, DOI 10.1016/j.jbiomech.2004.10.040
  40. Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P103, DOI 10.1007/s00223-008-9198-2
  41. Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
  42. Wenger NK, 1995, AM J HYPERTENS, V8, pS94, DOI 10.1016/0895-7061(95)99306-1
  43. Wiens M, 2006, J INTERN MED, V260, P350, DOI 10.1111/j.1365-2796.2006.01695.x
  44. Wu HC, 2013, J CELL BIOCHEM, V114, P1969, DOI 10.1002/jcb.24534
  45. Yang SM, 2011, BONE, V48, P451, DOI 10.1016/j.bone.2010.10.170
  46. Zhang YF, 2013, CHINESE MED J-PEKING, V126, P2661, DOI 10.3760/cma.j.issn.0366-6999.20121244

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17